XML 57 R43.htm IDEA: XBRL DOCUMENT v3.22.4
Stock-Based Compensation (Tables)
 12 Months Ended
Dec. 31, 2022
Stock-Based Compensation [Abstract]  
Stock-based compensation expense [Table Text Block]
Stock-based compensation expense for the years ended December 31, 2022, 2021 and 2020 is as follows:
Year Ended December 31,
(In thousands)202220212020
Stock options$1,327 $2,001 $1,878 
Restricted share units(1)
158,031 145,553 10,406 
Total stock-based compensation expense159,358 147,554 12,284 
Tax benefit recognized in the statements of earnings3,391 4,304 3,062 
Stock-based compensation expense, net of tax$155,967 143,250 $9,222 
(1) Includes expense of $143.2 million and $127.1 million for the twelve months ended December 31, 2022 and 2021, respectively in stock compensation expense related to 8,096,595 common shares issued to the former owners of Acima, as part of the Aggregate Stock Consideration subject to restricted stock agreements, and recorded to Other charges in our Consolidated Statements of Operations. Shares issued as part of the Aggregate Stock Consideration for the acquisition of Acima Holdings were not issued under the authorization of the 2021 Plan or any prior approved long-term incentive plan described above. See Note B and Note N for additional information.
Stock option activity [Table Text Block] Information with respect to stock option activity related to the Plans for the year ended December 31, 2022 follows:
Equity Awards
Outstanding		Weighted Average
Exercise Price		Weighted Average
Remaining Contractual Life		Aggregate Intrinsic
Value
(In thousands)
Balance outstanding at January 1, 20221,121,489 $22.68 
Granted— — 
Exercised(108,701)16.43 
Forfeited(97,930)28.64 
Expired(60,519)29.80 
Balance outstanding at December 31, 2022854,339 $22.29 5.37$3,594 
Exercisable at December 31, 2022610,844 $19.82 19.82$3,453 
Weighted average fair values of options granted [Table Text Block]
The weighted average fair values of the options granted under the Plans were calculated using the Black-Scholes method. There were no options granted in 2022. The weighted average grant date fair value and weighted average assumptions used in the option pricing models for 2021 and 2020 are as follows: 
 Year Ended December 31,
 20212020
Weighted average grant date fair value$14.94 $7.28 
Weighted average risk free interest rate0.49 %0.93 %
Weighted average expected dividend yield2.87 %4.75 %
Weighted average expected volatility50.29 %49.44 %
Weighted average expected life (in years)4.624.62
Nonvested restricted stock units activity [Table Text Block]
Information with respect to non-vested restricted stock unit activity follows:
Restricted Awards
Outstanding		Weighted Average
Grant Date Fair Value
Balance outstanding at January 1, 2022(1)
9,209,257 $50.33 
Granted1,224,764 25.50 
Vested(2)
(4,711,403)48.99 
Forfeited (3)
(545,133)41.41 
Balance outstanding at December 31, 2022(1)
5,177,485 $46.63 
(1) Includes 7,898,706 and 3,691,328 outstanding shares at January 1, 2022 and December 31, 2022 related to RSA agreements issued as part of the Aggregate Stock Consideration for the acquisition of Acima Holdings, described further in Note B, which were not issued under the authorization of the 2021 Plan or any previously approved long-term incentive plan described above.
(2) Includes 4,180,193 shares vested during 2022 as part of RSA agreements issued as part of the Aggregate Stock Consideration for the acquisition of Acima Holdings, as described above.
(3) Includes 27,185 shares forfeited during 2022 as part of RSA agreements issued as part of the Aggregate Stock Consideration for the acquisition of Acima Holdings, as described above.